Gliomatosis Cerebri disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: GLM004 MIFTS: 44	Gliomatosis Cerebri Categories: Cancer diseases, Mental diseases, Neuronal diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Gliomatosis Cerebri

MalaCards integrated aliases for Gliomatosis Cerebri:

Name: Gliomatosis Cerebri ¹¹ ¹⁹ ⁵⁸ ⁷⁵ ⁵³ ¹⁴ ⁷¹

Neoplasms, Neuroepithelial ⁴³

Astrocytosis Cerebri ¹¹

Characteristics:

Prevelance:

<1/1000000 (Europe) ⁵⁸

Age Of Onset:

Adult ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases Mental diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Neoplasms

Malignant neoplasms of eye, brain and other parts of central nervous system

Malignant neoplasm of brain

Malignant neoplasm: Cerebrum, except lobes and ventricles

Orphanet: ⁵⁸

Rare neurological diseases

External Ids:

Disease Ontology ¹¹ DOID:6128

MeSH ⁴³ D018302

NCIt ⁴⁹ C4318

SNOMED-CT ⁶⁸ 26138003

ICD10 via Orphanet ³² C71.0

UMLS via Orphanet ⁷² C0334576

Orphanet ⁵⁸ ORPHA251582

UMLS ⁷¹ C0334576

Sources

Summaries for Gliomatosis Cerebri

GARD: ¹⁹ Gliomatosis cerebri is a type of malignant (cancerous) brain tumor called a glioblastoma that develops from a specific type of brain cell called an astrocyte. It involves at least three sections (lobes) within the main part of the brain (cerebrum). It may also affect both sides of the cerebrum as well as the nerve cells within the brain (grey matter). There are two types of Gliomatosis cerebri. Type 1 (classic form) is characterized by scattered and widespread tumor cells and no apparent mass or tumor, while type 2 has similar characteristics in addition to a detectable mass or tumor. Signs and symptoms of Gliomatosis cerebri may include personality changes, memory disturbance, headaches, and seizures.

MalaCards based summary: Gliomatosis Cerebri, also known as neoplasms, neuroepithelial, is related to glioma susceptibility 1 and oligoastrocytoma, and has symptoms including headache, seizures and sensory manifestations. An important gene associated with Gliomatosis Cerebri is GFAP (Glial Fibrillary Acidic Protein), and among its related pathways/superpathways are Neural Stem Cells and Lineage-specific Markers and Pathways affected in adenoid cystic carcinoma. The drugs Neurotransmitter Agents and Psychotropic Drugs have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and eye, and related phenotypes are cellular and neoplasm

Orphanet: ⁵⁸ A rare glial tumor characterized by extensive infiltration of the brain, often extending to infratentorial structures and even the spinal cord. The tumor corresponds to WHO grade III and is composed of elongated glial cells typically resembling astrocytes. Cases in which the predominant cell type is oligodendroglial have also been described. Some tumors develop a circumscribed neoplastic mass in addition to the diffuse lesion, usually showing features of high-grade glioma. Clinical symptoms include dementia, headache, seizures, signs of increased intracranial pressure, and a variety of neurological deficits. Prognosis is generally poor.

Disease Ontology: ¹¹ A brain cancer that is characterized by a pattern of diffuse infiltration of the brain that affect various areas of the cerebral lobes and has material basis in abnormally proliferating cells, derives from glial cells.

Wikipedia: ⁷⁵ Gliomatosis cerebri is a rare primary diffuse brain tumor that has a poor prognosis. It is defined by... more...

Sources

Related Diseases for Gliomatosis Cerebri

Diseases related to Gliomatosis Cerebri via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 305)

#	Related Disease	Score	Top Affiliating Genes
1	glioma susceptibility 1	31.2	TP53 IDH2 IDH1 H3-3A
2	oligoastrocytoma	30.6	MGMT IDH2 GFAP
3	glioma	30.4	TP53 PTEN MGMT IDH2 IDH1
4	central nervous system cancer	30.4	TP53 MGMT KDM4C IDH1
5	hydrocephalus	30.1	TP53 PTEN NES GFAP
6	oligodendroglioma	30.1	TP53 PTEN OLIG2 MGMT IDH2 IDH1
7	high-grade astrocytoma	30.0	TP53 PTEN ATRX
8	2-hydroxyglutaric aciduria	30.0	KDM4C IDH2 IDH1
9	l-2-hydroxyglutaric aciduria	30.0	KDM4C IDH2 IDH1
10	neurofibromatosis, type i	29.9	TP53 PTEN KIAA1549 IDH1
11	high grade glioma	29.7	TP53 PTEN NES MGMT KDM4C GFAP
12	malignant astrocytoma	29.5	TP53 PTEN MGMT KDM4C IDH1 ATRX
13	obstructive hydrocephalus	29.4	OLIG2 KIAA1549 H3-3B H3-3A GFAP
14	enchondromatosis, multiple, ollier type	29.3	TP53 KDM4C IDH2 IDH1 ATRX
15	fibrillary astrocytoma	29.2	TP53 LUC7L2 KIAA1549 IDH2 IDH1 H3-3B
16	gemistocytic astrocytoma	29.1	TP53 PTEN MGMT IDH2 IDH1 GFAP
17	glioblastoma	29.0	TP53 PTEN OLIG2 NES MGMT IDH2
18	medulloblastoma	28.9	TP53 PTEN OLIG2 NES MGMT IDH1
19	brain cancer	28.8	TP53 PTEN OLIG2 NES MGMT KDM4C
20	meningioma, familial	28.6	TP53 PTEN OLIG2 MGMT KIAA1549 IDH1
21	diffuse astrocytoma	28.1	TP53 PTEN OLIG2 MGMT KIAA1549 KDM4C
22	anaplastic astrocytoma	27.7	TP53 PTEN OLIG2 NES MGMT KIAA1549
23	nervous system disease	27.5	TP53 PTEN OLIG2 NES MGMT LUC7L2
24	anaplastic oligodendroglioma	27.2	TP53 PTEN OLIG2 NES MGMT KIAA1549
25	pilocytic astrocytoma	27.2	TP53 PTEN OLIG2 NES MGMT KIAA1549
26	spinal cord disease	27.0	TP53 PTEN OLIG2 NES MGMT KIAA1549
27	low grade glioma	26.7	TP53 PTEN OLIG2 NES MGMT KIAA1549
28	glial tumor	10.5
29	intracranial hypertension	10.5
30	rare tumor	10.5
31	encephalitis	10.4
32	parkinsonism	10.3
33	low-grade astrocytoma	10.3
34	urethra transitional cell carcinoma	10.3	TP53 GFAP
35	intracranial hypertension, idiopathic	10.3
36	overgrowth syndrome	10.3
37	enchondroma	10.3	IDH2 IDH1
38	lung oat cell carcinoma	10.3	TP53 PTEN
39	prolactin producing pituitary tumor	10.3	TP53 MGMT
40	spinal cord lipoma	10.3	MGMT GFAP
41	synchronous bilateral breast carcinoma	10.3	TP53 PTEN
42	intracranial chondrosarcoma	10.2	IDH2 IDH1
43	cerebral lymphoma	10.2	MGMT IDH1
44	anaplastic oligodendroglioma, idh-mutant and 1p/19q-codeleted	10.2	IDH2 IDH1
45	periosteal chondrosarcoma	10.2	IDH2 IDH1
46	juxtacortical chondroma	10.2	IDH2 IDH1
47	glioblastoma classical subtype	10.2	MGMT IDH1
48	endometrioid ovary carcinoma	10.2	TP53 PTEN
49	sinonasal undifferentiated carcinoma	10.2	IDH2 IDH1
50	sclerosing hemangioma	10.2	TP53 PTEN

Graphical network of the top 20 diseases related to Gliomatosis Cerebri:

Sources

Symptoms & Phenotypes for Gliomatosis Cerebri

UMLS symptoms related to Gliomatosis Cerebri:

headache; seizures; sensory manifestations

MGI Mouse Phenotypes related to Gliomatosis Cerebri:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	9.65	ATRX GFAP H3-3A H3-3B IDH2 KDM4C
2	neoplasm	MP:0002006	9.63	IDH2 KDM4C MGMT OLIG2 PTEN TP53
3	mortality/aging	MP:0010768	9.36	ATRX GFAP H3-3A H3-3B IDH1 KDM4C

Sources

Drugs & Therapeutics for Gliomatosis Cerebri

Drugs for Gliomatosis Cerebri (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 71)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Neurotransmitter Agents

Phase 3

Psychotropic Drugs

Phase 3

Anticonvulsants

Phase 3

Pharmaceutical Solutions

Phase 3

Bevacizumab

Approved, Investigational

Phase 2

216974-75-3

135329020

Benzocaine

Approved, Investigational

Phase 2

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 2

1401-55-4

16129878 16129778

Gefitinib

Approved, Investigational

Phase 1, Phase 2

184475-35-2

123631

Pembrolizumab

Approved

Phase 2

1374853-91-4

254741536

Valproic acid

Approved, Investigational

Phase 2

99-66-1

3121

Temozolomide

Approved, Investigational

Phase 2

85622-93-1

5394

Doxorubicin

Approved, Investigational

Phase 2

23214-92-8

31703

Antineoplastic Agents, Immunological

Phase 2

Immunoglobulins

Phase 2

Antibodies, Monoclonal

Phase 2

Antibodies

Phase 2

Angiogenesis Inhibitors

Phase 1, Phase 2

Vaccines

Phase 1, Phase 2

Adjuvants, Immunologic

Phase 1, Phase 2

Interleukin-12

Phase 1, Phase 2

Anti-Bacterial Agents

Phase 2

Antibiotics, Antitubercular

Phase 2

Liposomal doxorubicin

Phase 2

Lenograstim

Approved, Investigational

Phase 1

135968-09-1

Trametinib

Approved

Phase 1

871700-17-3

11707110

Gemcitabine

Approved

Phase 1

95058-81-4, 122111-03-9

60750

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 1

1177-87-3

3680

Dexamethasone

Approved, Investigational, Vet_approved

Phase 1

50-02-2

3003 5743

Palbociclib

Approved, Investigational

Phase 1

571190-30-2

5330286

Mebendazole

Approved, Vet_approved

Phase 1

31431-39-7

4030

Piperazine

Approved, Vet_approved

Phase 1

110-85-0

4837

Protein Kinase Inhibitors

Phase 1

Antiviral Agents

Phase 1

Antimetabolites

Phase 1

Antineoplastic Agents, Hormonal

Phase 1

Gastrointestinal Agents

Phase 1

Hormones

Phase 1

Hormone Antagonists

Phase 1

Antiemetics

Phase 1

glucocorticoids

Phase 1

BB 1101

Phase 1

Anti-Inflammatory Agents

Phase 1

Piperazine citrate

Phase 1

DMP 777

Phase 1

157341-41-8

Dopamine

Approved

62-31-7, 51-61-6

681

Melphalan

Approved

Early Phase 1

148-82-3

4053 460612

Fludarabine

Approved

Early Phase 1

75607-67-9, 21679-14-1

30751 657237

Alemtuzumab

Approved, Investigational

Early Phase 1

216503-57-0

Etoposide

Approved

Early Phase 1

33419-42-0

36462

Thiotepa

Approved, Investigational

Early Phase 1

52-24-4

5453

Interventional clinical trials:

(show all 17)

#	Name	Status	NCT ID	Phase	Drugs
1	International Cooperative Phase III Trial of the HIT-HGG Study Group for the Treatment of High Grade Glioma, Diffuse Intrinsic Pontine Glioma, and Gliomatosis Cerebri in Children and Adolescents < 18 Years.(HIT-HGG-2013)	Recruiting	NCT03243461	Phase 3	Temozolomide + Valproic Acid
2	A Phase 2 Study of Valproic Acid and Radiation, Followed by Maintenance Valproic Acid and Bevacizumab in Children With Newly Diagnosed High-grade Gliomas or Brainstem Gliomas	Completed	NCT00879437	Phase 2	Valproic acid;Bevacizumab
3	Phase I/II Trial of Gefitinib and Radiation in Pediatric Patients Newly Diagnosed With Brain Stem Tumors or Incompletely Resected Supratentorial Malignant Gliomas With Phase II Limited to Brain Stem Tumors	Completed	NCT00042991	Phase 1, Phase 2	gefitinib
4	A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)	Completed	NCT02798406	Phase 2
5	Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients.	Recruiting	NCT04388033	Phase 1, Phase 2	Interleukin-12;Temozolomide
6	An Open-label, Single-arm, Phase II Study to Evaluate Safety and Efficacy of Doxorubicin in Combination With Radiotherapy, Temozolomide and Valproic Acid in Patients With Glioblastoma Multiforme (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG)	Terminated	NCT02758366	Phase 2	Doxorubicin
7	A First-in-human Phase I Single-agent Dose-escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms	Recruiting	NCT04541082	Phase 1	ONC206
8	Phase 1 Trial of Engineered HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors	Recruiting	NCT03911388	Phase 1
9	Molecularly-Driven Doublet Therapy for All Children With Refractory or Recurrent CNS Malignant Neoplasms and Young Adults With Refractory or Recurrent SHH Medulloblastoma	Active, not recruiting	NCT03434262	Phase 1	Gemcitabine;ribociclib;sonidegib;trametinib
10	A Phase I Study of Intratumoral/Peritumoral Herpes Simplex Virus-1 Mutant HSV1716 in Patients With Refractory or Recurrent High Grade Gliomas (HGG)	Terminated	NCT02031965	Phase 1	dexamethasone
11	Phase I Study of CDK 4-6 Inhibitor PD-0332991 (Palbociclib; IBRANCE) in Children With Recurrent, Progressive or Refractory Central Nervous System Tumors	Terminated	NCT02255461	Phase 1	palbociclib isethionate
12	Untersuchungen Zur Verlaufskontrolle Bei Re-Bestrahlung Von Glioblastompatienten Mittels Kombinierter [18F]FET-PET-Kernspintomographie	Unknown status	NCT01579253
13	Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers	Active, not recruiting	NCT02162732
14	The Expanded Access Use of Vorasidenib in Patients With IDH1 or IDH2 Mutated Glioma	Available	NCT05592743		Vorasidenib
15	18F-FDOPA PET/CT or PET/MRI in Patients With Gliomas	Terminated	NCT02175745		18F-fluoro-dihydroxyphenylalanine
16	A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors	Terminated	NCT02653196	Early Phase 1	Keratinocyte Growth Factor;Alemtuzumab;Thiotepa;Etoposide;Fludarabine;Melphalan;Tacrolimus;Cyclosporine A;Mycophenolate mofetil
17	Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors	Withdrawn	NCT02194452

Search NIH Clinical Center for Gliomatosis Cerebri

Cochrane evidence based reviews: neoplasms, neuroepithelial

Sources

Genetic Tests for Gliomatosis Cerebri

Sources

Anatomical Context for Gliomatosis Cerebri

Organs/tissues related to Gliomatosis Cerebri:

MalaCards : Brain, Spinal Cord, Eye, Temporal Lobe, Cerebellum, Pituitary, Breast

Sources

Publications for Gliomatosis Cerebri

Articles related to Gliomatosis Cerebri:

(show top 50) (show all 391)

#	Title	Authors	PMID	Year
1	Clinicopathological study of cellular proliferation and invasion in gliomatosis cerebri: important role of neural cell adhesion molecule L1 in tumour invasion. ⁵³ ⁶²	Suzuki T...Yoshimine T	15677537	2005
2	Analysis of TP53 and PTEN in gliomatosis cerebri. ⁵³ ⁶²	Mawrin C...Dietzmann K	12734658	2003
3	Assessment of proliferative potential in gliomatosis cerebri. ⁵³ ⁶²	Hara A...Mori H	1856741	1991
4	Glioblastoma with Gliomatosis Cerebri Growth Pattern Presenting as Rapidly Progressive Dementia. ⁶²	Rhee JY...Gonzalez Castro LN	35419153	2022
5	T2/FLAIR Hyperintensity in Mesial Temporal Lobe: Challenging Differential Diagnosis. ⁶²	Moon S	34931987	2022
6	Multifocal oligodendroglioma with callosal and brainstem involvement. ⁶²	Mubarak F...Qureshi MB	36324958	2022
7	Pediatric high-grade gliomas and the WHO CNS Tumor Classification-Perspectives of pediatric neuro-oncologists and neuropathologists in light of recent updates. ⁶²	Gielen GH...Kramm CM	35733513	2022
8	MRI findings in a young dog with gliomatosis cerebri. ⁶²	Liatis T...Gutierrez-Quintana R	34318514	2022
9	A rare case of gliomatosis cerebri lurking beneath the shadows of a stroke mimic. ⁶²	Prasad A...Sriwastava S	34345333	2021
10	Nimotuzumab therapy in the treatment of pediatric central nervous system tumors: single-center experience. ⁶²	Susam-Sen H...Akyuz C	34151393	2021
11	Leber's hereditary optic neuropathy with diffuse white matter changes mimicking gliomatosis cerebri: illustrative case. ⁶²	Saruta W...Kumabe T	35854899	2021
12	Fluctuation of Clinical Signs With Near-Syncopal Episodes in a Dog With Gliomatosis Cerebri: A Diagnostic Challenge. ⁶²	Tauro A...Stent A	33434679	2021
13	Canine Gliomatosis Cerebri: Morphologic and Immunohistochemical Characterization Is Supportive of Glial Histogenesis. ⁶²	Rissi DR...Miller AD	33357125	2021
14	Analysis of preventability of malignancy-related maternal death from the nationwide registration system of maternal deaths in Japan. ⁶²	Katsuragi S...Ikeda T	30999803	2021
15	Gliomatosis Cerebri Growth Pattern: Association of Differential First-Line Treatment with Overall Survival in WHO Grade II and III Gliomas. ⁶²	Dive I...Steinbach JP	33472203	2021
16	A pediatric case of anaplastic astrocytoma with a gliomatosis cerebri; the growth pattern and changes in serum VEGF-121 levels after bevacizumab treatment. ⁶²	Ninomiya H...Ohnishi H	33222957	2020
17	Predictive factors for overall survival in surgical cases of gliomatosis cerebri from the National Cancer Database. ⁶²	Khalafallah AM...Mukherjee D	33222914	2020
18	A phase I trial of lenalidomide and radiotherapy in children with diffuse intrinsic pontine gliomas or high-grade gliomas. ⁶²	Hipp SJ...Warren KE	33040274	2020
19	A case of pediatric gliomatosis cerebri harboring H3F3A K27 mutation. ⁶²	Nakano Y...Hara J	32965767	2020
20	Gliomatosis cerebri mimicking diffuse demyelinating disease: Case Report. ⁶²	Mingomataj E...Velayudhan V	32742528	2020
21	Gliomatosis cerebri (GC) or GC-like? A picture to be reconsidered in neuro-oncology based on large retrospective analysis of GC series. ⁶²	Anghileri E...Cuccarini V	32114667	2020
22	Multimodal neuroimaging of gliomatosis cerebri: a case series of four patients. ⁶²	Bonomi R...Juhasz C	32913666	2020
23	Gliomatosis cerebri and Rasmussen's encephalitis: Two different entities causing refractory epilepsy. Comparison through two clinical cases. ⁶²	Andermatten JA...Hinojosa J	32439411	2020
24	Outcomes of presumed malignant glioma treated without pathological confirmation: a retrospective, single-center analysis. ⁶²	Climans SA...Mason WP	33282325	2020
25	Mortal consequences of a cooperative action between Takotsubo syndrome and increased intracranial pressure. ⁶²	Alfano G...Del Gaudio S	32142222	2020
26	Clinical relevance of molecular subgrouping of gliomatosis cerebri per 2016 WHO classification: a clinicopathological study of 89 cases. ⁶²	Kwon MJ...Suh YL	31435963	2020
27	Adult H3K27M-mutant diffuse midline glioma with gliomatosis cerebri growth pattern: Case report and review of the literature. ⁶²	Yekula A...U HS	32145563	2020
28	Imaging characteristics of adult H3 K27M-mutant gliomas. ⁶²	Qiu T...Chu S	31731269	2019
29	Radiological Characteristics and Natural History of Adult IDH-Wildtype Astrocytomas with TERT Promoter Mutations. ⁶²	Izquierdo C...Ducray F	30407589	2019
30	Gliomatosis Cerebri: A Unique Presentation with Accompanying Clinical Nuance. ⁶²	Ordookhanian C...Kaloostian PE	31528509	2019
31	Corticosteroid-induced immunodeficiency in a patient with gliomatosis cerebri: Are corticosteroids indicated in all brain tumors? ⁶²	Car M...Popovic M	30964431	2019
32	Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors. ⁶²	Malzkorn B...Reifenberger G	31025086	2019
33	Gliomatosis Cerebri Among Children and Adolescents: An Individual-Patient Data Meta-analysis of 182 Patients. ⁶²	Georgakis MK...Petridou ET	30887873	2019
34	[Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors. German version]. ⁶²	Malzkorn B...Reifenberger G	30790013	2019
35	Wide Range of Clinical Outcomes in Patients with Gliomatosis Cerebri Growth Pattern: A Clinical, Radiographic, and Histopathologic Study. ⁶²	Ly KI...Dietrich J	30097523	2019
36	Heterogeneity of glioblastoma with gliomatosis cerebri growth pattern on diffusion and perfusion MRI. ⁶²	Forster A...Groden C	30565029	2019
37	An autopsy case of widespread brain dissemination of glioblastoma unnoticed by magnetic resonance imaging after treatment with bevacizumab. ⁶²	Hardian RF...Hongo K	31528472	2019
38	An Adolescent Presenting With Seizures as a Symptom of Gliomatosis Cerebri. ⁶²	Blanco-Iglesias E...Serrano A	28486262	2018
39	Prognostic Factors and Survival of Gliomatosis Cerebri: A Systematic Review and Meta-Analysis. ⁶²	Georgakis MK...Petridou ET	30172970	2018
40	Clinical, neuroimaging and histopathological features of gliomatosis cerebri: a systematic review based on synthesis of published individual patient data. ⁶²	Georgakis MK...Petridou ET	30117023	2018
41	Gliomatosis cerebri: a consensus summary report from the Second International Gliomatosis cerebri Group Meeting, June 22-23, 2017, Bethesda, USA. ⁶²	Morales La Madrid A...Warren KE	29998396	2018
42	Incidence and survival of gliomatosis cerebri: a population-based cancer registration study. ⁶²	Georgakis MK...Petridou ET	29464663	2018
43	Magnetic resonance imaging features of canine gliomatosis cerebri. ⁶²	Schweizer-Gorgas D...Steffen F	29110365	2018
44	WHO 2016 Classification of gliomas. ⁶²	Wesseling P...Capper D	28815663	2018
45	Gliomatosis Cerebri: A Rare Brain Tumor. ⁶²	Rahman MM...Lailatunnessa M	29459616	2018
46	Astroblastoma - reviewing literature and one case report. ⁶²	Teleanu DM...Bogaciu NS	30845307	2018
47	Lactoferrin- and RGD-comodified, temozolomide and vincristine-coloaded nanostructured lipid carriers for gliomatosis cerebri combination therapy. ⁶²	Zhang J...Mao G	29861635	2018
48	A Pediatric Case of Diffuse Glioma Diagnosed at Autopsy. ⁶²	Ross J...Fuller C	31240015	2017
49	Feline glioma: a retrospective study and review of the literature. ⁶²	Rissi DR...Miller AD	28156189	2017
50	2016 Updates to the WHO Brain Tumor Classification System: What the Radiologist Needs to Know. ⁶²	Johnson DR...Kaufmann TJ	29028423	2017

Sources

Genes for Gliomatosis Cerebri

Genes related to Gliomatosis Cerebri (0 elite genes):

(show all 14)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	GFAP	Glial Fibrillary Acidic Protein	Protein Coding	21.11	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15677537 1856741
2	PTEN	Phosphatase And Tensin Homolog	Protein Coding	19.45	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12734658
3	TP53	Tumor Protein P53	Protein Coding	13.09	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
4	IDH1	Isocitrate Dehydrogenase (NADP(+)) 1	Protein Coding	6.8	DISEASES inferred ¹⁴
5	LUC7L2	LUC7 Like 2, Pre-MRNA Splicing Factor	Protein Coding	6.22	DISEASES inferred ¹⁴ ¹⁴
6	MGMT	O-6-Methylguanine-DNA Methyltransferase	Protein Coding	6.04	DISEASES inferred ¹⁴
7	IDH2	Isocitrate Dehydrogenase (NADP(+)) 2	Protein Coding	5.91	DISEASES inferred ¹⁴
8	H3-3B	H3.3 Histone B	Protein Coding	5.88	DISEASES inferred ¹⁴
9	H3-3A	H3.3 Histone A	Protein Coding	5.87	DISEASES inferred ¹⁴
10	OLIG2	Oligodendrocyte Transcription Factor 2	Protein Coding	5.66	DISEASES inferred ¹⁴
11	KDM4C	Lysine Demethylase 4C	Protein Coding	5.63	DISEASES inferred ¹⁴ ¹⁴
12	ATRX	ATRX Chromatin Remodeler	Protein Coding	5.49	DISEASES inferred ¹⁴
13	NES	Nestin	Protein Coding	5.32	DISEASES inferred ¹⁴
14	KIAA1549	KIAA1549	Protein Coding	5.08	DISEASES inferred ¹⁴

Sources

Variations for Gliomatosis Cerebri

Sources

Expression for Gliomatosis Cerebri

Search GEO for disease gene expression data for Gliomatosis Cerebri.

Sources

Pathways for Gliomatosis Cerebri

Pathways related to Gliomatosis Cerebri according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Neural Stem Cells and Lineage-specific Markers ⁶⁵	11.23	OLIG2 NES GFAP
2	Pathways affected in adenoid cystic carcinoma ⁷⁴	10.92	TP53 PTEN ATRX
3	Transcription_Transcription factor Tubby signaling pathways ²²	10.85	TP53 H3-3B H3-3A
4	Effect of progerin on genes involved in Hutchinson-Gilford progeria syndrome ⁷⁴	10.37	TP53 H3-3B H3-3A